Prechoroidal cleft changes after intravitreal injections of Faricimab in treatment-naïve and nonresponders-to-aflibercept patients: A case series.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

European Journal of Ophthalmology Pub Date : 2025-02-26 DOI:10.1177/11206721251322541

Elisa Stradiotto, Alessandro Feo, Giovanni Ottonelli, Vanessa Ferraro, Claudia Del Turco, Claudio Panico, Mario R Romano, Carlo La Spina

{"title":"Prechoroidal cleft changes after intravitreal injections of Faricimab in treatment-naïve and nonresponders-to-aflibercept patients: A case series.","authors":"Elisa Stradiotto, Alessandro Feo, Giovanni Ottonelli, Vanessa Ferraro, Claudia Del Turco, Claudio Panico, Mario R Romano, Carlo La Spina","doi":"10.1177/11206721251322541","DOIUrl":null,"url":null,"abstract":"Purpose: To describe the clinical and optical coherence tomography (OCT) changes of prechoroidal cleft in treatment-naïve and non-naïve neovascular age-related macular degeneration (nAMD) treated with Faricimab intravitreal injections.Methods: A case series (4 eyes from 4 patients).Results: Cases 1 and 2 were diagnosed with treatment-naïve nAMD. Case 1 showed minimal prechoroidal cleft persistence after treatment with visual acuity stabilization. Case 2 showed prechoroidal cleft resolution, followed by its recurrence with neovascular reactivation. Cases 3 and 4 had a history of nAMD unresponsive to Aflibercept therapy. In Case 3, prechoroidal cleft reappearance occurred simultaneously to neovascular reactivation. In Case 4 prechoroidal cleft resolved rapidly after switching to Faricimab, but this was complicated by the development of a retinal pigment epithelium (RPE) tear.Conclusion: In this report, we highlight the importance of prechoroidal cleft as a negative prognostic OCT biomarker despite the increasingly proved efficacy of Faricimab. Pigment epithelium detachment height may correlate with the size of prechoroidal cleft and macular neovascularization (MNV) activity. Further studies are needed to better elucidate the prognostic significance of prechoroidal cleft after Faricimab therapy.","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251322541"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251322541","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To describe the clinical and optical coherence tomography (OCT) changes of prechoroidal cleft in treatment-naïve and non-naïve neovascular age-related macular degeneration (nAMD) treated with Faricimab intravitreal injections.

Methods: A case series (4 eyes from 4 patients).

Results: Cases 1 and 2 were diagnosed with treatment-naïve nAMD. Case 1 showed minimal prechoroidal cleft persistence after treatment with visual acuity stabilization. Case 2 showed prechoroidal cleft resolution, followed by its recurrence with neovascular reactivation. Cases 3 and 4 had a history of nAMD unresponsive to Aflibercept therapy. In Case 3, prechoroidal cleft reappearance occurred simultaneously to neovascular reactivation. In Case 4 prechoroidal cleft resolved rapidly after switching to Faricimab, but this was complicated by the development of a retinal pigment epithelium (RPE) tear.

Conclusion: In this report, we highlight the importance of prechoroidal cleft as a negative prognostic OCT biomarker despite the increasingly proved efficacy of Faricimab. Pigment epithelium detachment height may correlate with the size of prechoroidal cleft and macular neovascularization (MNV) activity. Further studies are needed to better elucidate the prognostic significance of prechoroidal cleft after Faricimab therapy.

查看原文本刊更多论文

在treatment-naïve和对aflibercept无反应的患者中，玻璃体内注射Faricimab后脉络膜前裂的变化：一个病例系列。

目的：探讨法瑞昔单抗玻璃体内注射治疗treatment-naïve和non-naïve新生血管性老年性黄斑变性（nAMD）患者脉络膜前裂的临床和光学相干断层扫描（OCT）变化。方法：4例患者4眼病例。结果：病例1、2诊断为treatment-naïve nAMD。病例1在视力稳定治疗后仍有轻微的脉络膜前裂。病例2表现为脉络膜前裂消退，随后复发伴新生血管再激活。病例3和4有nAMD史，对阿非利西普治疗无反应。病例3，脉络膜前裂再现与新生血管再激活同时发生。病例4在改用Faricimab后，脉络膜前裂迅速消退，但由于视网膜色素上皮（RPE）撕裂的发展而复杂化。结论：在本报告中，我们强调了脉络膜前裂作为阴性预后OCT生物标志物的重要性，尽管Faricimab的疗效越来越得到证实。色素上皮脱离高度可能与脉络膜前裂隙大小和黄斑新生血管（MNV）活性有关。需要进一步的研究来更好地阐明法利昔单抗治疗后脉络膜前裂的预后意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Ophthalmology 医学-眼科学

CiteScore

3.60

自引率

0.00%

发文量

372

审稿时长

3-8 weeks

期刊介绍： The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.